medigraphic.com
Academia Mexicana de Neurología, A.C.

2009, Número 2

<< Anterior Siguiente >>

Rev Mex Neuroci 2009; 10 (2)


Espasticidad en niños

García BC, Venta SJA, Hernández SJ, Navarro VJL

Idioma: Español
Referencias bibliográficas: 24
Paginas: 107-111
Archivo PDF: 58.22 Kb.


FRAGMENTO

La parálisis cerebral es la causa más frecuente de espasticidad en el niño, ocasiona trastornos en el movimiento y en la postura, como resultado de una lesión al sistema nervioso central (SNC).


REFERENCIAS (EN ESTE ARTÍCULO)

  1. Simpson DM, Gracies JM, Graham HK, et al. Assessment: Botulinum neurotoxin for the treatment of spasticity (an evidence-based review). Neurology 2008; 70: 1691-8.

  2. Pascual PSI. Tratamiento preventivo y paliativo con toxina botulínica de la cadera en el niño con parálisis cerebral infantil. Rev Neurol 2003; 37: 80-2.

  3. Sarioglu B, Serdaroglu G, Tutuncuoglu S, et al. The use of botulinum toxin type A treatment in children with spasticity. Pediatr Neurol 2003; 29: 299-301.

  4. Simpson LL. The origin, structure, and pharmacological activity of botulinum. Pharmacol Rev 1981; 33: 155-88.

  5. Dask TK, Park DM. Botulinum toxin in treatment spasticity. Br J Clin Pharmacol 1989; 43: 401-3.

  6. Crowner BE, Racette BA. Prospective study examining remote effects of botulinum toxin A in children with cerebral palsy. Pediatr Neurol 2008; 39: 253-8 Tabla 6 Músculos espásticos del tronco Músculos Dosis U/kg Puntos Botox/Dysport de inyección Opistotonus Paravertebrales dorsales 10 30 5 bilateral lumbares bilaterales Hiperlordosis lumbar Paravertebrales lumbares 10 30 5 bilateral bilarterales Escoliosis lumbar Paravertebrales unilaterales 5 15 5 unilateral Cuadrado lumbar 1-3 2-4 1

  7. Berweck S, Heinen F. Use of Toxin in Pediatric Spasticity (Cerebral Palsy). Mov Disord 2004; 19(Suppl. 8): S162-7.

  8. Gracies JM. Physiological Effects of Botulinum Toxin in Spasticity. Mov Disord 2004; 19(Suppl. 8): S120-8.

  9. Pascual-Pascual SI , Herrera-Galante A, Póo P. Guía terapéutica de la espasticidad infantil con toxina botulínica. Rev Neurol 2007; 44(5): 303-9.

  10. Willis AW, Crowner B, Brunstrom JE. High dose botulinum toxin A for the treatmeny of lower extremity hipertonicity in children with cerebral palsy. Developmental Medicine-Child Neurology 2007; 49: 818-22.

  11. Heinen F, Molenaers G, Fairhurst C, et al. European consensus table 2006 on Botulinum toxin for children with cerebral palsy-Eur J Pediatr Neurol 2006; 10: 215-25.

  12. Ashworth B. Preliminary trial of carisoprodol in multiple sclerosis. Practitioner 1964; 192: 540-2.

  13. Koman LA, Mooney JF, Smith BP. Management of spasticity in cerebal palsy with botulinum A toxin: Report of a preliminary,randomized,double-blind trial. J Pediatr Orthop 1994; 14: 209-303.

  14. Stuberp WA, Fuchs RH, Miedaner JA. Reliability of goniometric measurement of children with cerebral palsy. Dev Med Child Neurol 1988; 30: 657-66.

  15. O’Brien C. Management of spasticity associated with stroke in O’Brien C, Yablon S (eds.). Management of spasticity with botulinium toxin. Litleton, CO: Postgraduate Institute for Medicine; 1995, p. 7-15.

  16. Jacks LK, Michels DM, Smith BP. Clinical usefulness of botulinum toxin in the lower Extremity. Foot Ankle Clin N Am 2004; 9(2): 339-48.

  17. Póo P, Galván-Manso M, Casartelli MJ. Toxina botulínica en la parálisis cerebral infantil. Rev Neurol 2008; 47(Supl. 1): S21-24.

  18. Borodic GE, Perrante R, Pearce LB. Histologic assessment of dose related difusión and muscle fiber response alter therapeutic botulinium Atoxin injections. Mov Disord 1994; 9: 31-9.

  19. Wissel J, Heinen F, Schenkel A, et al. Botulinum Toxin A in the management of spastic gait disorders in children and young adults with cerebral palsy: a randomized,double-blind study of “highdose” versus “low-dose”treatment. Neuropediatrics 1999; 30: 120-4.

  20. Aoki KR.Pharmacology and Immunology of Botulinum Neurotoxins. Int Ophthalmol Clin 2005 Summer; 45(3): 25-37.

  21. Heinen F, Schroeder AS, Fietzek U, et al. When it comes to botulinum toxin,children and adults are not the same: Multimuscle option for children with cerebral palsy. Mov Disord 2006; 21: 2029-30.

  22. Sätilä H, Kotamäki A, Koivikko M- Low- and High- dose botulinum Toxin A treatment: a retrospective analisys. Pediatr Neurol 2006; 34: 285-90.

  23. Gormely ME, Herring GM, Gaebler-Spira DJ. The use of botulinum toxin in children: a retrospective study of adverse reactions and treatment of idiopathic toe walking. European Journal Neurology 1997; (Suppl. 4)(Suppl. 2): S27-30.

  24. Cosgrove AP, Graham HK. Botulinum Toxin A prevents the development of contractures in hereditary spastic muscle. Dev Med Child Neurol 1994; 36: 379-85.




2020     |     www.medigraphic.com